Refine
Year of publication
Has Fulltext
- yes (30)
Is part of the Bibliography
- no (30)
Keywords
- USP28 (3)
- proteomics (3)
- COVID-19 (2)
- Cancer (2)
- Proteomics (2)
- SARS-CoV-2 (2)
- TMT (2)
- autophagy (2)
- c-MYC (2)
- integrated stress response (2)
- lung cancer (2)
- mTOR (2)
- proteostasis (2)
- stress response (2)
- 2019-nCoV (1)
- 3′UTR length (1)
- AAA+ disaggregase (1)
- APA (1)
- ATM (1)
- Autoimmune vasculopathy (1)
- BAG3 (1)
- BRAF (1)
- Browsertool (1)
- Buparlisib (1)
- CFIm (1)
- CRISPR/Cas9 (1)
- Cas9 inhibitor (1)
- Cell Biology (1)
- Cell biology (1)
- Covid-19 (1)
- DNA-PK (1)
- Data Analysis (1)
- Degradation (1)
- Devic disease (1)
- Devic syndrome (1)
- EGFR (1)
- FIP1 (1)
- HRAS 28 Gefitinib (1)
- IR (1)
- IRF-3 (1)
- ISR (1)
- Innate immunity (1)
- Interferon (1)
- MACE-seq (1)
- MYC (1)
- Microbiology, Virology & Host Pathogen Interaction (1)
- Mitochondrial dysfunction (1)
- NF-kB (1)
- NMO-IgG (1)
- NOTCH (1)
- NSCLC (1)
- Neuromyelitis optica (1)
- Omicron (1)
- PI3K (1)
- PIK3CA (1)
- PROTAC (1)
- PTEN (1)
- Parkin (1)
- Perrault syndrome (1)
- Protein-translocation (1)
- Python (1)
- Rab7 (1)
- Radiotherapy (1)
- Research article (1)
- SILAC (1)
- SRSF3 (1)
- SRSF7 (1)
- Software (1)
- Stroke genetics (1)
- Systems & Computational Biology (1)
- Translation (1)
- Translation proteomics (1)
- Ubiquitin ligase (1)
- Vemurafenib (1)
- adipose-derived stromal/stem cells (1)
- antiviral (1)
- aprotinin (1)
- aquaporin-4 (AQP4) antibody (1)
- bioinformatics (1)
- buparlisib (1)
- c-JUN (1)
- calcitriol (1)
- cap-dependent translation (1)
- cell biology (1)
- cerebrospinal fluid (1)
- chemical-induced proximity (1)
- clinical features (1)
- coagulation (1)
- coagulopathy (1)
- dPAS (1)
- data analysis (1)
- differential expression (1)
- drug discovery (1)
- epidemiology (1)
- extracellular vesicles (1)
- gefitinib (1)
- genome editing (1)
- glioblastoma (1)
- glioblastoma stem-like cells (1)
- human (1)
- hypoxia (1)
- iCLIP (1)
- interactome (1)
- longitudinally extensive transverse myelitis (1)
- magnetic resonance imaging (1)
- mesenchymal stromal/stem cells (1)
- mitochondria (1)
- pPAS (1)
- protein quality control (1)
- pulse labeling (1)
- pulsed SILAC (1)
- recurrent optic neuritis (1)
- renal tubular epithelial cells (1)
- severe acute respiratory syndrome coronavirus (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- squamous cell carcinoma (1)
- statistics (1)
- stress (1)
- thrombosis (1)
- transferrin (1)
- translation (1)
- translatome (1)
- ubiquitin (1)
- unfolded protein response (1)
- vemurafenib (1)
- vitamin D3 (1)
- ΔNp63 (1)
- π-clamp (1)
Institute
MicroRNAs (miRNAs) are critical post-transcriptional regulators in many biological processes. They act by guiding RNA-induced silencing complexes to miRNA response elements (MREs) in target mRNAs, inducing translational inhibition and/or mRNA degradation. Functional MREs are expected to predominantly occur in the 3' untranslated region and involve perfect base-pairing of the miRNA seed. Here, we generate a high-resolution map of miR-181a/b-1 (miR-181) MREs to define the targeting rules of miR-181 in developing murine T-cells. By combining a multi-omics approach with computational high-resolution analyses, we uncover novel miR-181 targets and demonstrate that miR-181 acts predominantly through RNA destabilization. Importantly, we discover an alternative seed match and identify a distinct set of targets with repeat elements in the coding sequence which are targeted by miR-181 and mediate translational inhibition. In conclusion, deep profiling of MREs in primary cells is critical to expand physiologically relevant targetomes and establish context-dependent miRNA targeting rules.
Oncogenic transformation of lung epithelial cells is a multi-step process, frequently starting with the inactivation of tumor suppressors and subsequent activating mutations in proto-oncogenes, such as members of the PI3K or MAPK family. Cells undergoing transformation have to adjust to changes, such as metabolic requirements. This is achieved, in part, by modulating the protein abundance of transcription factors, which manifest these adjustments. Here, we report that the deubiquitylase USP28 enables oncogenic reprogramming by regulating the protein abundance of proto-oncogenes, such as c-JUN, c-MYC, NOTCH and ΔNP63, at early stages of malignant transformation. USP28 is increased in cancer compared to normal cells due to a feed-forward loop, driven by increased amounts of oncogenic transcription factors, such as c-MYC and c-JUN. Irrespective of oncogenic driver, interference with USP28 abundance or activity suppresses growth and survival of transformed lung cells. Furthermore, inhibition of USP28 via a small molecule inhibitor reset the proteome of transformed cells towards a ‘pre-malignant’ state, and its inhibition cooperated with clinically established compounds used to target EGFRL858R, BRAFV600E or PI3KH1047R driven tumor cells. Targeting USP28 protein abundance already at an early stage via inhibition of its activity therefore is a feasible strategy for the treatment of early stage lung tumours and the observed synergism with current standard of care inhibitors holds the potential for improved targeting of established tumors.
MicroRNAs (miRNAs) are critical post-transcriptional regulators in many biological processes. They act by guiding RNA-induced silencing complexes to miRNA response elements (MREs) in target mRNAs, inducing translational inhibition and/or mRNA degradation. Functional MREs are expected to predominantly occur in the 3' untranslated region and involve perfect base-pairing of the miRNA seed. Here, we generate a high-resolution map of miR-181a/b-1 (miR-181) MREs to define the targeting rules of miR-181 in developing murine T-cells. By combining a multi-omics approach with computational high-resolution analyses, we uncover novel miR-181 targets and demonstrate that miR-181 acts predominantly through RNA destabilization. Importantly, we discover an alternative seed match and identify a distinct set of targets with repeat elements in the coding sequence which are targeted by miR-181 and mediate translational inhibition. In conclusion, deep profiling of MREs in primary cells is critical to expand physiologically relevant targetomes and establish context-dependent miRNA targeting rules.
Oncogenic transformation of lung epithelial cells is a multistep process, frequently starting with the inactivation of tumour suppressors and subsequent development of activating mutations in proto-oncogenes, such as members of the PI3K or MAPK families. Cells undergoing transformation have to adjust to changes, including altered metabolic requirements. This is achieved, in part, by modulating the protein abundance of transcription factors. Here, we report that the ubiquitin carboxyl-terminal hydrolase 28 (USP28) enables oncogenic reprogramming by regulating the protein abundance of proto-oncogenes such as c-JUN, c-MYC, NOTCH and ∆NP63 at early stages of malignant transformation. USP28 levels are increased in cancer compared with in normal cells due to a feed-forward loop, driven by increased amounts of oncogenic transcription factors such as c-MYC and c-JUN. Irrespective of oncogenic driver, interference with USP28 abundance or activity suppresses growth and survival of transformed lung cells. Furthermore, inhibition of USP28 via a small-molecule inhibitor resets the proteome of transformed cells towards a ‘premalignant’ state, and its inhibition synergizes with clinically established compounds used to target EGFRL858R-, BRAFV600E- or PI3KH1047R-driven tumour cells. Targeting USP28 protein abundance at an early stage via inhibition of its activity is therefore a feasible strategy for the treatment of early-stage lung tumours, and the observed synergism with current standard-of-care inhibitors holds the potential for improved targeting of established tumours.
Background: Despite advances in treatment of patients with non-small cell lung cancer, carriers of certain genetic alterations are prone to failure. One such factor frequently mutated, is the tumor suppressor PTEN. These tumors are supposed to be more resistant to radiation, chemo- and immunotherapy.
Results: We demonstrate that loss of PTEN led to altered expression of transcriptional programs which directly regulate therapy resistance, resulting in establishment of radiation resistance. While PTEN-deficient tumor cells were not dependent on DNA-PK for IR resistance nor activated ATR during IR, they showed a significant dependence for the DNA damage kinase ATM. Pharmacologic inhibition of ATM, via KU-60019 and AZD1390 at non-toxic doses, restored and even synergized with IR in PTEN-deficient human and murine NSCLC cells as well in a multicellular organotypic ex vivo tumor model.
Conclusion: PTEN tumors are addicted to ATM to detect and repair radiation induced DNA damage. This creates an exploitable bottleneck. At least in cellulo and ex vivo we show that low concentration of ATM inhibitor is able to synergise with IR to treat PTEN-deficient tumors in genetically well-defined IR resistant lung cancer models.